FDA Ponders Trimming PDUFA Programs
This article was originally published in The Tan Sheet
Acting Commissioner Ostroff considers whether all aspects of the user fee program are delivering maximum added value.
You may also be interested in...
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
Companies currently face little risk in seeking the designation because there is no financial cost and FDA denial is confidential.
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.